

4.0.03 DOC Cmte minutes

- **Principle** – record the Committee meeting attendance, running, discussions
- **Links to include** – none
- **Attachments to include** – none
- **Info to include** – guideline title; meeting date/location; status of minutes (draft/confirmed); attendees; observers; apologies; agenda items and related discussions; declarations of interest; date of next meeting

Subarachnoid haemorrhage committee meeting 11

Date: 13/1/2020

Location: Boardroom, National Guideline Centre, Royal College of Physicians, 11 St Andrews Place, London NW1 4LE

Minutes: Final

Committee members present:

Robert Henderson (Chair)	
Julie Cox	
Kenan Deniz	
Louise Dulhanty	
Olivier Gaillemin	
Nandan Gautam (Topic adviser)	
Jane Gooch	
Robert Lenthall	
Aidan Marsh	
James Piercy	
Anh Tran	
Dewi Williams (co-opted expert adviser)	

In attendance:

Ian Mather	Business Analyst & Resource Impact Assessment Lead, NICE	
Vimal Bedia	Systematic Reviewer,	

4.0.03 DOC Cmte minutes

	NGC	
Emma Cowles	Senior Health Economist, NGC	
Ben Mayer	Senior Research Fellow, NGC	
Gill Ritchie	Associate Director/Guideline Lead, NGC	
Audrius Stonkus	Research Fellow, NGC	
Amelia Unsworth	Senior Project Manager, NGC	

Observers:

None	
------	--

Apologies:

Caroline Keir	Guideline Commissioning Manager, NICE
---------------	---------------------------------------

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 11th meeting on subarachnoid haemorrhage. The Committee members and attendees introduced themselves.

The Chair informed the Committee that 1 apology had been received. This is noted above.

The Chair outlined the objectives of the meeting, which included: discussion of the draft recommendations and impact and rationale for the review questions on monitoring for raised intracranial pressure and vasospasm, imaging strategies for follow-up and diagnostic accuracy & strategies, and evidence for the review questions on risk of subsequent SAH, long-term medicines to reduce the risk of subsequent SAH and long-term medicines to manage the consequences of SAH.

Introductions

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the

4.0.03 DOC Cmte minutes

matters under discussion were:

- Monitoring for raised intracranial pressure and vasospasm
- Imaging strategies for follow-up
- Diagnostic accuracy & strategies
- Risk of subsequent SAH
- Long-term medicines to reduce the risk of subsequent SAH
- Long-term medicines to manage the consequences of SAH.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Aidan Marsh	Consultant in Anaesthesia and Intensive Care Medicine, North Bristol NHS Trust	Presented an abstract in the form of a poster entitled 'Aneurysmal subarachnoid haemorrhage: an analysis of 663 consecutive patients admitted to a tertiary neurosurgical intensive care unit.' to the Intensive Care Society State of the Art meeting in December 2019, 13.1.20	Direct non-financial	No action needed other than process of open declaration

The Chair and a senior member of the Developer's team noted that the interest declared did not prevent the attendee from fully participating in the meeting.

3. Review GC10 draft recommendations, rationale & impact section

The Committee discussed the draft recommendations, rationale & impact section for the review question on monitoring for raised intracranial pressure and vasospasm.

4.0.03 DOC Cmte minutes

4. Review GC10 draft recommendations, rationale & impact section
The Committee discussed the draft recommendations, rationale & impact section for the review question on imaging strategies for follow-up.
5. Review GC10 draft recommendations, rationale & impact section
The Committee discussed the draft recommendations, rationale & impact section for the review question on diagnostic accuracy & strategies.
6. Evidence review
The Committee was given a presentation on the clinical and cost-effectiveness evidence for the review question on risk of subsequent SAH.
7. Evidence review
The Committee was given a presentation on the clinical and cost-effectiveness evidence for the review question on long-term medicines to reduce the risk of subsequent SAH.
8. Evidence review
The Committee was given a presentation on the clinical and cost-effectiveness evidence for the review question on long-term medicines to manage the consequences of SAH.
9. Minutes of the last meeting
The Committee agreed the minutes of the last meeting were an accurate record.
10. Any other business
None

Date of next meeting: 28/02/2020

Location of next meeting: Boardroom, National Guideline Centre, Royal College of Physicians, 11 St Andrews Place, London NW1 4LE